基本信息
浏览量:183
职业迁徙
个人简介
It has an extensive scientific productivity, with more than 230 scientific articles in indexed journals with a cumulative number of citations exceeding 5,000. He has extensive experience in supervising research work (master, doctorate and post-doctorate), including about 40 students, of whom 34 have already finished their theses. He is regularly invited to perform the role of reviewer,also belonging to the editorial board of several scientific journals. He has already received several national and international awards that reinforce the visibility and quality of the work he has been developing throughout his career.
He is Technical Director of ICNAS Produção (a company wholly owned by the University of Coimbra), having actively participated in obtaining the first radiopharmaceutical medicine developed and registered in Portugal (Fluodeoxyglucose [18F] UC). Its contribution to the development of the first medicinal Portuguese to be marketed (Eslicarbazepine Acetate; Antiepileptic; Zebinix®) and, more recently, the Opicapone (Antiparkinsonic; Ongentys®) [BIAL Laboratories].
Researcher and leader of the Pharmacology Group of the Centre for Neuroscience and Cell Biology (CNC) of the University of Coimbra, Amílcar Falcão is the author and co-author of several hundred scientific papers and publications. With several ongoing fundamental and applied research projects, with most of the funding supported by national and multinational pharmaceutical companies, his scientific activity has earned him several awards throughout his professional career, notably the "Eminent Sicentist of the Year - Clinical Pharmacology" (2006) and the "Almofariz Award - Person of the Year" (2008).
He was directly involved in the development of the first Portuguese medicine (Eslicarbazepine Acetate - Zebinix®) as a consultant for BIAL Laboratories.
He is Technical Director of ICNAS Produção (a company wholly owned by the University of Coimbra), having actively participated in obtaining the first radiopharmaceutical medicine developed and registered in Portugal (Fluodeoxyglucose [18F] UC). Its contribution to the development of the first medicinal Portuguese to be marketed (Eslicarbazepine Acetate; Antiepileptic; Zebinix®) and, more recently, the Opicapone (Antiparkinsonic; Ongentys®) [BIAL Laboratories].
Researcher and leader of the Pharmacology Group of the Centre for Neuroscience and Cell Biology (CNC) of the University of Coimbra, Amílcar Falcão is the author and co-author of several hundred scientific papers and publications. With several ongoing fundamental and applied research projects, with most of the funding supported by national and multinational pharmaceutical companies, his scientific activity has earned him several awards throughout his professional career, notably the "Eminent Sicentist of the Year - Clinical Pharmacology" (2006) and the "Almofariz Award - Person of the Year" (2008).
He was directly involved in the development of the first Portuguese medicine (Eslicarbazepine Acetate - Zebinix®) as a consultant for BIAL Laboratories.
研究兴趣
论文共 415 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ana Beatriz Santos,Andreia Carona,Miren Ettcheto,Antoni Camins,Amílcar Falcão, Ana Fortuna,Joana Bicker
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2024): 118-130
HEALTHCAREno. 1 (2024): 57
Nick Holford, Conor J. O'Hanlon,Karel Allegaert,Brian Anderson,Amilcar Falcao,Nicolas Simon,Yoke-Lin Lo,Alison H. Thomson,Catherine M. Sherwin,Evelyne Jacqz-Aigrain, Carolina Llanos-Paez,Stefanie Hennig,
BRITISH JOURNAL OF CLINICAL PHARMACOLOGYno. 4 (2024): 1066-1080
Biochemical Pharmacologypp.116184-116184, (2024)
APPLIED SCIENCES-BASELno. 10 (2023): 6348-6348
引用1浏览0引用
1
0
International journal of pharmaceutics (2023): 123145-123145
Pharmaceuticsno. 6 (2023): 1704-1704
引用1浏览0WOS引用
1
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn